LEADER 00000cam a2200445 a 4500 
001    ocm54026869  
003    OCoLC 
005    20231222090935.0 
008    040114s2003    nyua          001 0 eng d 
020    0971301735 
020    9780971301733 
035    (OCoLC)54026869 
040    USU|beng|cUSU|dOCLCQ|dKLG|dMMU|dOCLCQ|dOCLCO|dOCLCQ|dOCLCO
       |dSTJ 
049    STJJ 
050  4 RC552.S62|bS63 2003 
060  4 WM 600|bS678 2003 
082 04 616.8914 
092    616.8914|bS678S 
245 00 Social anxiety disorder :|bresearch and practice /
       |c[edited by] Mark H. Pollack, Naomi M. Simon, Michael W. 
       Otto. 
260    New York :|bProfessional Pub. Group,|c©2003. 
300    xii, 208 pages :|billustrations, tables ;|c24 cm 
336    text|btxt|2rdacontent 
337    unmediated|bn|2rdamedia 
338    volume|bnc|2rdacarrier 
500    "Sponsored by Wyeth Pharmaceuticals." 
500    Includes index (pages 205-208). 
505 0  Social anxiety disorder: phenomenology, epidemiology and 
       comorbidity -- Early antecedents of social anxiety 
       disorder: from risk to prevention -- Quality of life in 
       social anxiety disorder -- Cross-cultural aspects of 
       social anxiety disorder: the influence of culture on the 
       expression of mental distress -- Neurobiology of social 
       anxiety disorder -- Considering mechanism of action in the
       treatment of social anxiety disorder -- Pharmacotherapy of
       social anxiety disorder: current practice and future 
       promise -- Cognitive-behavioral therapy for social anxiety
       disorder. 
650  0 Social phobia|xPsychology. 
650  0 Antisocial personality disorders|xPsychology. 
650  0 Interpersonal relations|xPsychology. 
650 12 Social Behavior Disorders|xpsychology
       |0(DNLM)D012920Q000523 
650 22 Antisocial Personality Disorder|xpsychology
       |0(DNLM)D000987Q000523 
700 1  Pollack, Mark H. 
700 1  Simon, Naomi M. 
700 1  Otto, Michael W. 
994    C0|bSTJ